Charles River 4Q Financial Results

Charles River
4Q Revenues: $1.10 billion (+21%)
4Q Earnings: $187.4 million (+36%)
FY Revenues: $3.98 billion (+12%)
FY Earnings: $492.6 million (+24%)

Comments: The addition of a 53rd week at the end of 2022, contributed approximately 5.8% to reported fourth-quarter revenue growth. The acquisition of Explora BioLabs contributed 1.8% to consolidated fourth-quarter revenue growth, and the divestitures of the Research Models and Services operations in Japan (RMS Japan) and the CDMO site in Sweden (CDMO Sweden) and the Avian Vaccine business reduced reported revenue growth by 0.5%.

Fourth quarter revenue for the Research Models and Services (RMS) segment was $196.1 million, an increase of 18%. The Explora BioLabs acquisition and the addition of the 53rd week contributed 10.1% and 4.5%, respectively, to RMS revenue growth in the quarter.

Revenue for the Discovery and Safety Assessment (DSA) segment was $691.7 million in the quarter, up 29.5%.

Fourth quarter revenue for the Manufacturing segment was $212.1 million, an increase of 3%.